DISCOUNT ZERTIFIKAT - VERTEX PHARMACEUTICALS | Real-time Bid/Ask 04:59:00 2024-06-10 EDT | ||
| 318.07 EUR / 319.44 EUR | +0.63% |
|
| Current month | +1.20% | ||
| 1 month | +2.08% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-07 | 316.8 | +0.75% |
| 24-06-06 | 314.4 | -0.08% |
| 24-06-05 | 314.6 | +0.37% |
| 24-06-04 | 313.5 | +0.00% |
| 24-06-03 | 313.5 | +0.14% |
Delayed Quote Börse Stuttgart
Last update June 07, 2024 at 12:49 pm
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | ME7D8Q |
| ISIN | DE000ME7D8Q0 |
| Date issued | 2024-01-23 |
| Maturity | 2024-12-20 (194 Days) |
| Parity | 1 : 1 |
| Emission price | 302.9 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 316.8 € |
|---|---|
| Lowest since issue | 297.4 € |
| Spread | 1.33 € |
| Spread % | 0.42% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
483
USD
Average target price
463.5
USD
Spread / Average Target
-4.04%
- Stock Market
- Certificates
- Certificat
